EpiTech MAG
Noninvasive Magnetic Therapy for Dry Eye Disease
Company Overview
Snapshot
Founded in March 2015 by Itzik Ronen, EpiTech MAG operated with 1–10 employees. The company secured $2.05 million across two funding rounds from two investors, with its last disclosed funding round in November 2018.
Business overview
EpiTech MAG developed a noninvasive medical device and method for treating dry eye syndrome. Its proprietary technology, Viveye, utilized repetitive magnetic stimulation to target the peripheral branches of the trigeminal nerve, aiming to reinforce the ocular surface's structural integrity. This noninvasive ocular neurostimulation therapy was designed to provide a zero-contact, affordable, and easily adoptable solution for long-lasting relief from dry eye symptoms, serving the healthcare industry within the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is EpiTech MAG's core technology?
- EpiTech MAG developed a proprietary noninvasive ocular neurostimulation therapy based on repetitive magnetic stimulation. This technology uses targeted magnetic fields to stimulate the peripheral branches of the trigeminal nerve, aiming to reinforce the ocular surface's structural integrity.
- When was EpiTech MAG founded?
- EpiTech MAG was founded in March 2015.
- What is the primary medical condition EpiTech MAG's technology addresses?
- EpiTech MAG's technology is designed for the noninvasive treatment of dry eye syndrome.
- Who is a co-founder of EpiTech MAG?
- Itzik Ronen is a co-founder and VP R&D at EpiTech MAG.
- What is the current status of EpiTech MAG?
- EpiTech MAG is currently non-active, having ceased to operate in September 2022.